Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Toulouse – page 44

1 504 clinical trials in Toulouse, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Toulouse at a glance
1 504
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 504 trials in Toulouse

Open in trial search

Colon cancer

Recruiting

Study on the Effectiveness of Chemotherapy with Folinic Acid, Fluorouracil, and Irinotecan for Patients with Stage III Colon Cancer After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Glomerulonephritis membranoproliferative

Recruiting

Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Adenocarcinoma of colon

Recruiting

Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Methylmalonic acidaemia

Recruiting

Study on Long-Term Safety of mRNA-3705 for Patients with Methylmalonic Acidemia (MMA)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Dexamethasone
  • Sponsor:Moderna Therapeutics Inc.

Nephrolithiasis

Recruiting

Study on the Effect of Furosemide and Amiloride Hydrochloride on Kidney Stone Fragments After Laser Treatment in Patients Undergoing Flexible Ureteroscopy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Furosemide
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Acute myeloid leukaemia+1

Recruiting

Study Comparing Thymoglobulin and Grafalon for Preventing Graft Versus Host Disease in Elderly Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Assistance Publique Hopitaux De Paris

Ovarian cancer

Recruiting

Study of Abemaciclib and Letrozole for Patients with Estrogen Receptor Positive Low-Grade Serous Ovarian Cancer and Adult-Type Granulosa Cell Tumor

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:UZ Leuven

Interstitial lung disease

Recruiting

Study on Long-Term Safety of Inhaled Treprostinil for Patients with Fibrotic Lung Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Oesophageal squamous cell carcinoma

Recruiting

Study Comparing Chemoradiotherapy with Fluorouracil, Cisplatin, and Carboplatin for Patients with Operable Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Karolinska University Hospital

Progressive multifocal leukoencephalopathy

Recruiting

Study of Pembrolizumab for Progressive Multifocal Leukoencephalopathy in Immunocompromised Patients Without HIV

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Uveitis

Recruiting

Study Comparing Adalimumab and Mycophenolate Mofetil for Patients with Steroid-Dependent Non-Infectious Uveitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic scleroderma

Recruiting

Study on the Use of Allogenic Adipose-Tissue-Derived Mesenchymal Stem Cells for Healing Chronic Digital Ulcers in Systemic Sclerosis Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Toulouse

What the registry says about research in the country

01 Cardiovascular and Metabolic Research

Innovative studies focusing on heart disease treatment, including trials for TTR amyloidosis and prevention of heart failure. Advanced therapeutic approaches using novel compounds like baxdrostat in combination with established medications.

  • TTR Amyloidosis Cardiomyopathy
  • Heart Failure Prevention
  • Cardiovascular Risk Management
02 Oncology Studies

Comprehensive cancer research targeting multiple types of malignancies, including head and neck cancer, gastric cancer, and advanced pancreatic cancer. Novel approaches using targeted therapies and immunotherapy combinations.

  • Head & Neck Squamous Cell Carcinoma
  • Gastric and GEJ Cancer
  • Pancreatic Cancer
  • Non-Small Cell Lung Cancer
03 Neurological Disorders

Advanced research in neurodegenerative conditions and movement disorders, including studies on frontotemporal dementia, essential tremor, and traumatic brain injury outcomes.

  • Frontotemporal Dementia
  • Essential Tremor
  • Traumatic Brain Injury
  • Multiple Sclerosis
04 Autoimmune and Inflammatory Conditions

Studies investigating new treatments for inflammatory diseases, including innovative approaches for Crohn's disease, psoriatic arthritis, and myasthenia gravis.

  • Crohn's Disease
  • Psoriatic Arthritis
  • Myasthenia Gravis
  • Idiopathic Pulmonary Fibrosis
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.